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A gas-chromatographic method on capillary columns is described
for measuring concentrations of total PCBs and of six PCB conge-
ners, PCB-28, PCB-52, PCB-101, PCB-138, PCB-153 and PCB-180,
in human blood serum. Recovery of compounds was evaluated, and
the repeatability and reproducibility of the results tested on sam-
ples analysed on the same day and over a period of two years. The
method was verified in an international AQA study in three rounds
of measurements. The method was applied for the analysis of 45
serum samples collected in Zagreb, Croatia. All samples contained
PCB-138 and PCB-153; the incidence of the other congeners was
between 80 and 98%.
Key words: polychlorinated biphenyls, PCBs, PCB congeners, hu-
man blood serum.
INTRODUCTION
Polychlorinated biphenyls (PCBs) are a group of 209 congeners differing
in the number and position of chlorine on the biphenyl. They have been in
use for numerous purposes (capacitors, transformers, textile and paper in-
dustry) for more than half a century, always in mixtures containing up to
60% of chlorine. No congener was used for any other purpose but research.
Thanks to the discovery of PCBs presence in environmental samples by S.
Jensen1 and his »The PCB Story«, PCBs have been found in almost all envi-
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ronmental and human samples; they are also the group of most investigated
compounds. PCB mixtures used commercially contain up to 100 congeners
and they have been found in environmental and human samples depending
on the exposure, time elapsed from the exposure and on degradation condi-
tions. The analysis of PCBs in human and environmental samples faces the
problem of low concentration levels and of the large number of congeners in
every mixture. The method of choice is gas chromatography (GC) with elec-
tron capture detection (ECD), particularly linked to mass spectrometry. Due
to different toxicities of the congeners, high resolution gas chromatography
on capillary columns is applied, enabling congener specific analysis.2
In the past, PCBs were determined on packed GC columns and total
PCB levels were determined by the summation of several peaks in compari-
son to the sum of the corresponding peaks in the solution of commercial
PCB mixtures.3,4 Due to the differences in chlorine contents of commercial
mixtures and differences in chromatographic conditions, results obtained in
different laboratories are not always comparable because different PCB
peaks are evaluated. Furthermore, it was not possible to identify individual
congeners because every peak represented more than one compound. To
overcome these problems, the perchlorination procedure was introduced
into the analysis of PCBs in order to measure total PCBs, expressed as de-
cachlorobiphenyl.5 Toxicological research showed, however, that PCB conge-
ners differ greatly in their toxic potential and the information on the distri-
bution of individual congeners is important. Therefore, the perchlorination
method has been discarded.
EXPERIMENTAL
Analysed Compounds and Analytical Procedure
The PCBs analysis in human blood started in our laboratory in 1985 on packed
GC columns using Aroclor 1260, one of the commercial PCB mixtures, containing
60% of chlorine and Aroclor 1016 containing 41.5% of chlorine as standards for PCBs
determination.4
Humans are exposed to various mixtures of PCBs. The PCB pattern in human
body depends therefore on the source of exposure. Due to the different stability and
rate of metabolic degradation of PCB congeners not all congeners remain present in
the human body at measurable levels. Aroclor 1260 and Aroclor 1016 contain almost
a hundred congeners each, but under chromatographic conditions applied for packed
gas chromatographic columns congeners are not separated and appear in the chro-
matogram in nearly twenty well defined peaks. Therefore, each peak represents
more than one congener. When quantitation was done on packed columns, more
than six PCB congeners (but not individually identified) were quantified and there-
fore total PCB levels were higher than the sum of the invidually analysed congeners.
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When monitoring of the general population is performed, individual results for each
person are not of general interest. Therefore, establishing a national ratio between
the results obtained on packed columns using Aroclors for quantification and the re-
sults obtained in comparison with selected PCB congeners is of interest for the fu-
ture research and monitoring as well as comparison of old data with those obtained
using high resolution GC and quantitation as compared to individual PCB conge-
ners.
This paper presents the analysis of six selected congeners, most frequently
found in human and environmental samples. The aim was to introduce congener
specific analysis of PCBs in human serum/plasma using high resolution GC with
capillary columns, and compare the obtained results with the levels of total PCBs.
Samples were therefore also analysed in comparison with Aroclor 1260. This mix-
ture was chosen because it best represents the compounds present in human blood.
The compounds were determined either in plasma or serum because no difference
was found between these two media.
The six analysed PCB congeners are listed in Table I. They were purchased from
Promochem GmbH, Germany. Aroclor 1260 containing 60% chlorine was obtained
from the US Environmental Protection Agency.
Blood samples were collected by venipuncture in heparinized or nonheparinized
test-tubes from donors of the general population and from exposed workers. Se-
rum/plasma were separated by centrifugation and stored at –20 °C until analysis.
Extraction was performed in the following way: 1.0 mL of serum/plasma was
mixed with 1.0 mL formic acid and 1.0 mL n-hexane for l min. Compounds were ex-
tracted four times with 3.0 mL n-hexane. Extracts were combined and mixed with
1.0 mL 5% K2CO3 solution. Extracts were evaporated to about 4 mL and purified
with 5 mL concentrated sulfuric acid. Extracts were evaporated to dryness and resi-
dues were dissolved in 1.0 mL n-hexane prior the GC analysis.
The method was previously used for the determination of organochlorine pesti-
cides and total PCBs,3 and is a modification of the method published by Dale and
Miles.6
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TABLE I
Chemical names and IUPAC numbers of six PCBs congeners









– TRACOR 550 dual channel with two 63Ni electron capture detectors and two
packed columns.
Columns: glass columns 2 m long, 2 mm I.D.; 3% OV-1 on Chromosorb WHP
80/100 mesh; 5% OV-101 on Chromosorb DMCS AW 80/100 mesh.
Carrier gas: nitrogen. Temperature: inlet, 250 °C; columns, 210 °C; detectors,
260 °C.
– ATI UNICAM 610 dual channel capillary column gas chromatograph with two
63Ni electron capture detectors and split/splitless injectors.
Columns: 30 m capillary column fused silica 0.25 mm I.D., SPB-1701 0.25 mm
film thickness; 60 m capillary column fused silica 0.25 mm I.D., SPB-5 0.25 mm film
thickness.
Carrier gas: nitrogen. Injection: splitless, 3–5 mL.
Temperature programme: 30 m column – initial temperature 110 °C, ramp 4
°C/min, upper temperature 240 °C for 55 min; 60 m column – initial temperature
100 °C, ramp 4 °C/min, upper temperature 240 °C for 55 min.
All samples were analysed on two columns. Only peaks identified on both col-
umns were quantified as compared to the external standard via peak heights.
RESULTS AND DISCUSSION
Recovery of Compounds and Reproducibility of Results
Recovery of compounds was tested by adding 1.0 mL of the compound
solution in n-hexane to a mixture of serum/plasma and formic acid, and the
procedure was continued as described above. Compounds were added at two
concentration levels and ten parallel samples at each concentration level
were extracted on the same day. Results are presented in Table II. When
compounds were added in the range 1.5–4.1 ng mL–1 (depending on the com-
pound), recoveries were 68–87% and relative standard deviations of repeat-
ability of the results were 14–38%. At higher concentration ranges (3.7–10.2
ng mL–1 depending on the compound), recoveries were not markedly higher
(range 80–112%), but the repeatability of the results was better, with the
exception of PCB-52 where overlapping peaks of unknown impurity influ-
enced the results. The average recovery for both levels was 76–95% and the
relative standard deviation for reproducibility was 86% for PCB-52 and
16–34% for the other five PCB congeners.
Recovery and reproducibility were also tested on a long-term basis by
analysing 13 samples over a period of two years. Four solutions of com-
pounds were used for recovery testing. Concentration ranges of compounds
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added are given in Table III. Recoveries were in the range 60–86% depend-
ing on compounds and relative standard deviation for the reproducibility of
the results was in the range 18–61%. The highest RSD were obtained for
PCB-138 and PCB-153.
Analytical Quality Assurance
In order to be comparable with other laboratories in different countries,
we have participated in quality assurance studies for the analysis of PCB
congeners in human plasma.
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TABLE II
Recovery of compounds in 10 paralel samples at each concentration level analysed
on the same day
Compound











PCB-28 1.9 86 (20) 4.8 95 (14) 90 (22)
PCB-52 1.5 79 (31) 3.7 112 (72) 95 (87)
PCB-101 3.8 68 (38) 9.5 84 (15) 76 (34)
PCB-138 3.5 87 (14) 8.8 92 (12) 89 (16)
PCB-153 3.2 83 (18) 8.0 92 (13) 87 (18)
PCB-180 4.1 78 (18) 10.2 80 (17) 79 (20)
aRelative standard deviation in parentheses.
TABLE III





PCB-28 1.98–3.05 66 (25)
PCB-52 0.76–2.77 83 (29)
PCB-101 1.82–2.77 60 (18)
PCB-138 2.02–3.18 79 (57)
PCB-153 1.22–3.20 86 (61)
PCB-180 1.56–4.10 65 (34)
aRelative standard deviation in parentheses.
The method was tested in three rounds of an international quality as-
surance study (1994–1995) co-ordinated by the Deutsche Gesellschaft für
Arbeitsmedizin und Umweltmedizin e.V., Erlangen, Germany. Plasma sam-
ples were spiked with PCB congeners at four different concentrations: two
concentrations at environmental level and two concentrations at occupa-
tional exposure levels. Acceptance criterion: the results were accepted when
they were within  3 standard deviations of the mean value reported by the
reference laboratories.7
Our results are summarized in Table IV and compared with the results
reported from the other participating laboratories. The number of the other
laboratories varied from 10 to 26 depending on the round. In all rounds and
on both levels we have correctly determined the PCB-138 concentration;
PCB-28 was correctly determined in three rounds of the lower concentration
level, and PCB-180 in three rounds of the higher concentration level. The
number of positive results for PCB-52, PCB-101 and PCB-153 was about the
same as reported for the other laboratories.
Concentrations of PCB Congeners in Human Serum Samples
The method outlined above was applied to the analysis of PCB conge-
ners in the serum of 15 workers (14 male and 1 female, 31–58 years old)
occupationally exposed to PCBs and in the serum of 30 individuals (25 male
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TABLE IV
Results of the Interlaboratory Quality Assurance Study, expressed as
percent of positive resultsa
Compound











PCB-28 0.25–4.30 100 67 1.60–6.74 83 59 92 64
PCB-52 0.15–2.09 67 65 0.97–5.35 33 57 50 62
PCB-101 0.15–2.03 50 60 0.97–4.07 50 53 50 57
PCB-138 0.43–3.02 100 64 2.99–7.73 100 51 100 59
PCB-153 0.71–3.24 67 64 3.02–7.32 17 48 42 57
PCB-180 0.48–3.26 50 53 2.18–5.41 100 54 75 53
aIMI refers to our Institute.
and 5 female, 14–83 years old) from the general population (Table V). In the
group of occupationally exposed workers, total PCBs were also measured
and concentrations were determined as compared to Aroclor 1260 (Table V).
In 13 sera, out of 15, the concentration of total PCBs was higher than
the sum of the six congeners. The mean ratio of total PCBs/sum of conge-
ners was 1.8, and the median ratio was 1.4. This indicates that more than
six congeners were probably present in these sera. The correlation coeffi-
cients between total PCB concentrations and concentrations of PCB-180,
PCB-153 and PCB-138 were high: 0.94, 0.92 and 0.84 resp. For the other
three congeners these correlations were below 0.65.
All 45 samples contained PCB-138 and PCB-153. The incidence of the
other four congeners was 80% (PCB-28 and PCB-101), 96% (PCB-180) and
98% (PCB-52). Concentrations of the six congeners were on average slightly
higher in the sera of exposed workers than in the general population. The
concentrations of PCB-153 correlated best with the sum of the six congeners
(r = 0.79), while the corresponding coefficients for PCB-138 and PCB-180
were 0.72 and 0.66 resp., and for the other three compounds they were be-
low 0.60.
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TABLE V
Median concentrations / mg L–1 and concentration ranges (in brackets) of PCB
congeners and total PCBs in serum samples collected from exposed workers
(in 1994) and from the general population (in 1995 and 1997)a
Compound Exposed workers8 General population8,9
1994 (N = 15) 1995 (N = 14) 1997 (N = 16)
PCB-28 0.4 (0–3.8) 0.1 (0–0.3) 0.2 (0–0.5)
PCB-52 1.6 (0–4.6) 0.7 (0.3–1.5) 2.5 (0.5–9.1)
PCB-101 0.6 (0–0.7) 0.4 (0–3.4) 0.5 (0–2.4)
PCB-138 0.9 (0.3–4.6) 0.5 (0.2–1.2) 0.5 (0.2–4.6)
PCB-153 1.3 (0.3–5.2) 0.5 (0.3–1.6) 0.5 (0.1–2.4)
PCB-180 0.9 (0–2.8) 0.3 (0.2–2.7) 0.3 (0–0.9)
Sum PCB 6.6 (1.1–20.5) 2.4 (1.5–6.4) 4.4 (1.9–11.4)
Tot PCB 9 (3–29) – –
aZero stands for concentrations below detection limits. Sum PCB is the sum of six congener
concentrations. Tot PCB is the concentration of total PCBs. N is the number of serum samples.
If the concentration of a given congener showed a high correlation with
the concentration of total PCBs, or with the sum of all congeners, that com-
pound might be suggested as a marker in monitoring studies. No data are
available on the levels of the individual PCBs in the population of Croatia,
except for the small group described in this paper. However, a study on 800
Swedish male individuals showed a high correlation (r = 0.98) between total
PCBs and PCB-153, and the authors suggested that in monitoring studies
PCB-153 could be used as an indicator of total PCBs.10 Further congener
specific studies are required before a recommendation can be given for the
population of Croatia.
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SA@ETAK
Specifi~na analiza pojedinih poliklorbifenila (PCB) u serumu ljudi
iz Hrvatske
Blanka Krauthacker i Elsa Reiner
Opisana je plinskokromatografska analiza visoke djelotvornosti za odre|ivanje
koncentracije ukupnih PCB i {est pojedina~nih PCB (PCB-28, PCB-52, PCB-101,
PCB-138, PCB-153 i PCB-180) u serumu ljudi. Evaluirana su iskori{tenja i utvr|ena
ponovljivost i usporedivost rezultata analize uzoraka tijekom jednog dana i unutar
razdoblja od dvije godine. Metoda je potvr|ena sudjelovanjem u tri kruga mjerenja
me|unarodnog programa provjere kvalitete analize PCB u serumu. Provjerenom
metodom analizirano je 45 uzoraka seruma sakupljenih u Zagrebu. Svi uzorci sa-
dr`avali su PCB-138 i PCB-153, a ostali PCB na|eni su u 80–98% uzoraka.
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